Alnylam Pharmaceuticals, INC Form 4 insider transactions

Alnylam Pharmaceuticals' CFO, Jeffrey V. Poulton, reported the vesting of performance-based stock units and subsequent mandatory sales to cover tax obligations.

Alnylam Pharmaceuticals' Chief Commercial Officer, Tolga Tanguler, acquired shares from a performance-based unit vesting and subsequently sold shares to cover tax obligations.

Alnylam Pharmaceuticals' CSO and EVP, Kevin Fitzgerald, reported the vesting of performance-based stock units and subsequent sell-to-cover transactions for tax obligations.

Alnylam Pharmaceuticals director Stuart A. Arbuckle was granted 3,279 stock options with a vesting schedule over three years.

Alnylam Pharmaceuticals CEO Yvonne Greenstreet reported exercising multiple stock options and a subsequent disposition of shares on November 26, 2025, adjusting her beneficial ownership.

Alnylam Pharmaceuticals CSO & EVP, Head of Research, Kevin Joseph Fitzgerald, exercised stock options and subsequently sold a significant number of common shares under a pre-arranged trading plan.

Alnylam Pharmaceuticals CEO Yvonne Greenstreet executed pre-planned transactions, exercising stock options and subsequently selling a portion of the acquired shares.

Bryan Supran, EVP, CLO and Secretary of Alnylam Pharmaceuticals, Inc., was granted 13,026 restricted stock units.

Alnylam Pharmaceuticals' CFO Jeffrey Poulton acquired shares from performance-based vesting tied to Phase 3 clinical study initiation, followed by mandatory tax-related sales.

Alnylam Pharmaceuticals CEO Yvonne Greenstreet reported the vesting of performance-based stock units and subsequent tax-related sales of common stock.

Alnylam Pharmaceuticals' EVP, Chief Commercial Officer, Tolga Tanguler, acquired shares through PSU vesting and subsequently sold a portion to cover tax obligations.

Alnylam Pharmaceuticals' CSO and EVP, Kevin Fitzgerald, acquired 4,953 shares through performance-based stock unit vesting and subsequently sold 2,238 shares to cover tax obligations.

Alnylam Pharmaceuticals' EVP Chief R&D, Pushkal Garg, sold shares to cover tax obligations following the vesting of performance-based stock units tied to Phase 3 clinical study initiations.

Alnylam Pharmaceuticals Director Colleen F. Reitan exercised 18,000 stock options and subsequently sold 18,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

Alnylam Pharmaceuticals' Chief Commercial Officer, Tolga Tanguler, sold 3,474 shares of common stock on August 29, 2025, through a pre-arranged 10b5-1 trading plan.

Alnylam Pharmaceuticals EVP Chief R&D, Pushkal Garg, sold shares following the vesting of performance-based stock units and to cover tax obligations.

Alnylam Pharmaceuticals' Chief Commercial Officer, Tolga Tanguler, reported the vesting of performance-based stock units and subsequent sale of shares to cover tax obligations.

Alnylam Pharmaceuticals' CFO, Jeffrey V. Poulton, disclosed future stock acquisitions from performance-based vesting and subsequent sales for tax obligations under a pre-arranged plan.

Alnylam Pharmaceuticals CEO Yvonne Greenstreet acquired shares from PSU vesting and sold a portion to cover tax obligations.

Alnylam Pharmaceuticals' CSO and EVP, Kevin Fitzgerald, acquired 2,851 shares through PSU vesting and sold 1,396 shares to cover tax obligations.

Michael W. Bonney, a director at Alnylam Pharmaceuticals, exercised stock options and sold shares under a prearranged trading plan.

Alnylam Pharmaceuticals Director Dennis A. Ausiello exercised stock options and sold an equivalent number of shares on August 14, 2025, under a pre-arranged 10b5-1 trading plan.

Alnylam Pharmaceuticals' Chief Scientific Officer and EVP, Head of Research, Kevin Joseph Fitzgerald, was granted 7,763 restricted stock units, vesting over three years, and acquired additional shares through the company's 401(k) matching program.

Alnylam Pharmaceuticals CEO Yvonne Greenstreet engaged in pre-scheduled transactions, exercising stock options and selling common stock, as part of a Rule 10b5-1(c) trading plan.

Director Michael Bonney exercised stock options and sold shares of Alnylam Pharmaceuticals under a pre-arranged Rule 10b5-1 trading plan.

CEO Yvonne Greenstreet transferred 8,376 shares of Alnylam Pharmaceuticals common stock to an irrevocable trust for estate planning purposes.

Director David E.I. Pyott reports acquisition of restricted stock units and stock options in Alnylam Pharmaceuticals.

Director Colleen F. Reitan reports acquisition and disposal of Alnylam Pharmaceuticals stock and stock options.

Director Amy Schulman reports acquisition of stock and option awards in Alnylam Pharmaceuticals.

Director Charles Elliott Sigal reports acquisition of restricted stock units and stock options in Alnylam Pharmaceuticals.